Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Latest Information Update: 20 Oct 2022
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 08 Jun 2021 Results of safety and efficacy in interim data analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 26 Jan 2021 Planned End Date changed from 1 Jul 2022 to 1 Dec 2024.
- 26 Jan 2021 Status changed from recruiting to active, no longer recruiting.